This article is more than 5 years old. Information may no longer be current.

Aciex issued patents for allergic conjunctivitis, postoperative inflammation agents

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aciex Therapeutics announced that the United States Patent and Trademark Office has issued two separate U.S. patents for compositions within the allergy and ophthalmic market.

Patent No. 8,829,005 covers compositions of AC-170, a novel formulation of the oral antihistamine cetirizine ophthalmic solution 0.24%, which is being evaluated for the treatment of allergic conjunctivitis. A pre-New Drug Application meeting with the U.S. Food and Drug Administration is expected to occur by the end of the first quarter in 2015, according to a press release from Aciex.

Patent No. 8,765,725 covers compositions of AC-155, a novel nanocrystalline formulation of fluticasone, which is being developed for the first time for topical ocular administration for the treatment of postoperative inflammation and pain. It is expected to move into phase 2 clinical trials in 2015, subject to FDA agreement, completion of toxicity studies and filing of an Investigational New Drug application, according to the release.

On July 1, 2014, Nicox signed an agreement to acquire Aciex Therapeutics.